• Carmen Martínez, Jorge Gayoso, Carmen Canals, Hervé Finel, Karl Peggs, Alida Dominietto, Luca Castagna, Boris Afanasyev, Stephen Robinson, Didier Blaise, Paolo Corradini, Maija Itälä-Remes, Arancha Bermúdez, Edouard Forcade, Domenico Russo, Michael Potter, Grant McQuaker, Ibrahim Yakoub-Agha, Christof Scheid, Adrian Bloor, Silvia Montoto, Peter Dreger, Anna Sureda, and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
• Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.
• J. Clin. Oncol. 2017 Oct 20; 35 (30): 3425-3432.

AbstractPurpose To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD). Patients and Methods We retrospectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98), SIB (n = 338), or MUD (n = 273) transplantation. Results Median follow-up of survivors was 29 months. No differences were observed between groups in the incidence of acute graft-versus-host disease (GVHD). HAPLO was associated with a lower risk of chronic GVHD (26%) compared with MUD (41%; P = .04). Cumulative incidence of nonrelapse mortality at 1 year was 17%, 13%, and 21% in HAPLO, SIB, and MUD, respectively, and corresponding 2-year cumulative incidence of relapse or progression was 39%, 49%, and 32%, respectively. On multivariable analysis, relative to SIB, nonrelapse mortality was similar in HAPLO ( P = .26) and higher in MUD ( P = .003), and risk of relapse was lower in both HAPLO ( P = .047) and MUD ( P < .001). Two-year overall survival and progression-free survival were 67% and 43% for HAPLO, 71% and 38% for SIB, and 62% and 45% for MUD, respectively. There were no significant differences in overall survival or progression-free survival between HAPLO and SIB or MUD. The rate of the composite end point of extensive chronic GVHD and relapse-free survival was significantly better for HAPLO (40%) compared with SIB (28%; P = .049) and similar to MUD (38%; P = .59). Conclusion Post-transplantation cyclophosphamide-based HAPLO transplantation results in similar survival outcomes compared with SIB and MUD, which confirms its suitability when no conventional donor is available. Our results also suggest that HAPLO results in a lower risk of chronic GVHD than MUD transplantation.

36 keywords...

hide…